Tao Wang

Tao Wang

Auto-generated profile, based on publicly available information

Tao Wang

Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2012 in Respiratory Research
Verified
Journal Article
Open access
PDF file
ZLZenglin Liao
Zenglin Liao
JDJiajia Dong
Jiajia Dong
WWWei Wu
Wei Wu
TYTing Yang
Ting Yang
TWTao Wang
Tao Wang
FWFuqiang Wen
Fuqiang Wen
Background: Docosahexaenoic acid (DHA) and DHA-derived lipid mediators have recently been shown to possess anti-inflammatory and pro-resolving properties. In fact, DHA can down-regulate lipolysaccharide (LPS)-induced activation of NF-κB via a PPARγ-dependent pathway. We sought to investigate the effects of the novel DHA-derived mediator resolvin D1 (RvD1) on LPS-induced acute lung injury and to determine whether these effects occur via a PPARγ-dependent pathway. Methods: BALB/c mice aged 6–8 weeks were randomly divided into seven groups: two control groups receiving saline or RvD1 (600 ng) without LPS; a control group receiving LPS only; an experimental group receiving RvD1 (300 ng) or RvD1 (600 ng), followed by LPS; a group receiving the PPARγ antagonist GW9662; and a group receiving GW9662, then RvD1 (600 ng) and finally LPS. LPS (50 μM) and saline were administered intratracheally. RvD1 was injected intravenously 24 h and 30 min before LPS, while GW9662 was injected intravenously 30 min before RvD1. Mice were killed at 6, 12, and 24 h. Samples of bronchoalveolar lavage fluid (BALF) were analyzed for cell counts and cytokine analysis. Lung tissues were collected for histology, Western blotting and electrophoretic mobility shift assays (EMSAs). Results: At all three time points, groups receiving either dose of RvD1 followed by LPS had significantly lower total leukocyte counts and levels of TNF-α and IL-6 levels in BALF than did the group given only LPS. RvD1 markedly attenuated LPS-induced lung inflammation at 24 h, based on hematoxylin-eosin staining of histology sections. RvD1 activated PPARγ and suppressed IκBα degradation and NF-κB p65 nuclear translocation, based on Western blots and EMSAs. The PPARγ inhibitor GW9662 partially reversed RvD1-induced suppression of IκBα degradation and p65 nuclear translocation. Conclusions: These results suggest that RvD1 may attenuate lung inflammation of LPS-induced acute lung injury by suppressing NF-κB activation through a mechanism partly dependent on PPARγ activation.

31 December 2012 in Peptides
Verified
Journal Article
Closed access
ZLZenglin Liao
Zenglin Liao
JDJiajia Dong
Jiajia Dong
XHXiaorong Hu
Xiaorong Hu
TWTao Wang
Tao Wang
CWChun Wan
Chun Wan
FWFuqiang Wen
Fuqiang Wen

15 April 2014 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
YSYongchun Shen
Yongchun Shen
HZHong Zhu
Hong Zhu
CWChun Wan
Chun Wan
LCLei Chen
Lei Chen
TWTao Wang
Tao Wang
FWFuqiang Wen
Fuqiang Wen
Many studies have investigated whether pleural cholesterol levels can aid in diagnosis of pleural exudates, and the results have varied considerably. To gain a more reliable answer to this question, we meta-analyzed the literature on using pleural cholesterol or the ratio of cholesterol in pleural fluid to cholesterol in serum (P/S cholesterol ratio) as diagnostic tests to help identify pleural exudates.